Tetsu Inada is the Chief Financial Officer, Global Oncology Business Unit (OBU) at Takeda and has led the global Finance function since joining OBU in May 2021.
Mr. Inada joined Takeda in 2008 in the acquisition of Millennium Pharmaceuticals, and during his over 20 years at both companies, Mr. Inada held a variety of roles in finance, strategic planning, business development, and portfolio management. Prior to joining OBU, Mr. Inada was the Chief Financial Officer for the Global Vaccine Business Unit (VBU) at Takeda where he oversaw the finance, business planning and operations, contracts, and alliance management functions. He helped to build the organization from its early startup days, secure key product and funding partnerships, and invest across R&D, Manufacturing, Medical, and Commercial to advance a pipeline of innovative vaccines.
Before joining Takeda, Mr. Inada was a management consultant with Arthur D. Little focused on strategy development for multi-national chemical companies.
Mr. Inada holds a Bachelor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology (MIT), and an MBA in Financial Management from the MIT Sloan School of Management.